Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews-Reference-Cited by-同舟云学术

Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews

Published:2017-11-09 Issue:1 Volume:15 Page:
ISSN:1478-4505
Container-title:Health Research Policy and Systems
language:en
Short-container-title:Health Res Policy Sys

Author:

Mulinari Shai^ORCID,Davis Courtney

Funder

Vetenskapsrådet

Economic and Social Research Council

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s12961-017-0259-8.pdf

Reference54 articles.

1. Moynihan R. Was the flu drug zanamivir a breakthrough or money for old rope? BMJ. 2014;348:g3611.

2. Doshi P. Neuraminidase inhibitors—the story behind the Cochrane review. BMJ. 2009;339:b5164.

3. UK House of Commons Committee of Public Accounts. Access to Clinical Trial Information and the Stockpiling of Tamiflu. London: House of Commons Science and Technology Committee; 2014. https://www.publications.parliament.uk/pa/cm201314/cmselect/cmpubacc/295/295.pdf . Accessed 1 June 2017.

4. Burls A, Clark W, Stewart T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess. 2002;6(9):1–87.

5. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–9.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

2. “Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation;BioSocieties;2022-12-14

3. Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU;Social Science & Medicine;2021-07

4. Integrated analysis of RNA-binding proteins in human colorectal cancer;World Journal of Surgical Oncology;2020-08-22

5. Sociologiska perspektiv på coronakrisen;Sociologisk Forskning;2020-04-09